The association between COMT Val158Met gene polymorphism and antipsychotic-induced tardive dyskinesia risk.
Catechol-O-methyltransferase (COMT) Val158Met gene polymorphism has been implicated the association with Tardive dyskinesia (TD) risk. However, lots of studies have reported contradictory results, so we conducted a meta-analysis to investigate the association between the COMT Val158Met gene polymorphism and TD susceptibility. The PubMed, Embase, China National Knowledge Internet and Wanfang Database were researched up to 5 January 2015. The odds ratio (OR) and 95% confidence interval (95% CI) were used to assess the relationship, and the statistical analyses were carried out by STATA 11.0 software. In total, 1206 cases and 1680 controls from 11 case-control studies were included in the present study. The overall and subgroup pooled results indicated no significant association between COMT Val158Met gene polymorphism and TD susceptibility in all gene models (AA + AG vs. 0.98, 95% CI = 0.76-1.26, P = 0.87; AA vs. AG + 1.15, 95% CI = 0.93-1.42, P = 0.271; AA vs. 1.15, 95% CI = 0.90-1.49, P = 0.27; AG vs. 0.95, 95% CI = 0.80-1.14, P = 0.59; A vs. 1.05, 95% CI = 0.93-1.17, P = 0.43). The study suggested COMT Val158Met gene polymorphism may not be an independent risk factor for TD susceptibility, especially in East Asians.